… death in patients with HFimpEF to a similar extent as in those … In this post hoc report, we
evaluated the mode of death of … of dapagliflozin with reductions in cause-specific death in …

… to Improve the LIVEs of Patients With Preserved Ejection … of dapagliflozin on mortality and
the composite of death from … at higher ejection fractions reported in the EMPEROR trials 12 , …

… fraction, oral dapagliflozin improved heart failure outcomes to a … risk of worsening heart failure
or cardiovascular death by 18… We also assessed (post hoc) efficacy of dapagliflozin within …

… with cardiovascular (cardiovascular death or heart failure … analysis of the Dapagliflozin
Evaluation to Improve the Lives … level in this trial, 24 we evaluated a post hoc kidney composite …

… recurrent HF hospitalization and cardiovascular death), as well as improved KCCQ scores,
… variability of results with different post hoc EF cut points in the EMPEROR trials (eg, benefit in …

… In DAPA-HF, dapagliflozin also improved symptoms and … In addition to usual limitations of
post hoc analyses of trials, there … of DELIVER and DETERMINE (trials using dapagliflozin) in …

… , cardiovascular death, and all-cause death and improved symptoms, … outcomes by sex was
done post hoc. The proportion of … These findings provide further support for dapagliflozin as a …

… to enroll patients with heart failure and reduced ejection fraction. … In a post hoc sensitivity
analysis, we included trial site as an … was not improved significantly by dapagliflozin overall). In …

… treatment approaches to improve outcomes following HF … First, this was a post hoc analysis
of a clinical trial; therefore, … in the DAPA-HF trial and the DELIVER trial, as well as fees for …

… Last, our data do not provide any further information on how the … , and symptoms were
improved by dapagliflozin, in comparison … : a post hoc analysis of two randomised controlled trials.…